Larrey D, Distlerath L M, Dannan G A, Wilkinson G R, Guengerich F P
Biochemistry. 1984 Jun 5;23(12):2787-95. doi: 10.1021/bi00307a039.
Genetic polymorphism in oxidative drug metabolism is perhaps best exemplified in the case of debrisoquine 4-hydroxylase activity, where the incidence of deficient metabolism ranges from 1% to 30% in various populations and this defect is also linked to an impaired ability to metabolize a number of other drugs effectively. Sprague-Dawley (SD) rats possess this activity, but females of the DA strain do not, although total cytochrome P-450 (P-450) levels are similar. We have purified, by using debrisoquine 4-hydroxylase activity as an assay, a minor P-450 to electrophoretic homogeneity from male SD rats and designate this as P-450UT-H. P-450UT-H differs from eight other purified rat liver P-450s as judged by peptide mapping and immunochemical analysis and thus appears to be isozymic with these other P-450s. P-450UT-H exhibited considerably more debrisoquine 4-hydroxylase activity than any of the other purified P-450s and, on a total P-450 basis, more than total microsomal P-450. Antibodies raised against P-450UT-H specifically recognized P-450UT-H and inhibited more than 90% of the debrisoquine hydroxylase activity present in SD rat liver microsomes. The level of P-450UT-H in SD rat liver microsomes accounted for less than 10% of the total P-450, as judged by immunochemical quantitation. These assays also indicated that the level of P-450UT-H in female DA rat liver microsomes is only about 5% of that in male or female SD rat liver microsomes, consonant with the view that deficiency of this form of P-450 is responsible for the defective debrisoquine 4-hydroxylase activity in the former animals.(ABSTRACT TRUNCATED AT 250 WORDS)
氧化药物代谢中的遗传多态性在异喹胍4-羟化酶活性方面或许体现得最为明显。在不同人群中,代谢缺陷的发生率在1%至30%之间,并且这种缺陷还与有效代谢许多其他药物的能力受损有关。斯普拉格-道利(SD)大鼠具有这种活性,但DA品系的雌性大鼠则没有,尽管总的细胞色素P-450(P-450)水平相似。我们以异喹胍4-羟化酶活性作为检测指标,从雄性SD大鼠中纯化出一种次要的P-450,使其达到电泳纯,并将其命名为P-450UT-H。通过肽图谱分析和免疫化学分析判断,P-450UT-H与其他八种纯化的大鼠肝脏P-450不同,因此似乎与这些其他P-450是同工酶。P-450UT-H表现出的异喹胍4-羟化酶活性比任何其他纯化的P-450都要高得多,并且基于总的P-450计算,其活性超过了总的微粒体P-450。针对P-450UT-H产生的抗体能特异性识别P-450UT-H,并抑制SD大鼠肝脏微粒体中超过90%的异喹胍羟化酶活性。通过免疫化学定量分析判断,SD大鼠肝脏微粒体中P-450UT-H的水平占总P-450的比例不到10%。这些检测还表明,雌性DA大鼠肝脏微粒体中P-450UT-H的水平仅约为雄性或雌性SD大鼠肝脏微粒体中该酶水平的5%,这与认为前一种动物中这种形式的P-450缺乏是导致异喹胍4-羟化酶活性缺陷的观点一致。(摘要截短至250字)